Akèy › Leksemi mieloïd egi › Missouri › St. Louis
Etid klinik pou Leksemi mieloïd egi nan St. Louis, MO
22 etid pou Leksemi mieloïd egi ap chèche patisipan nan sit nan ak bò kote St. Louis (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Ap rekriteFaz 2
- Washington University School of Medicine, St Louis
- Siteman Cancer Center-South County, St Louis
- Missouri Baptist Medical Center, St Louis
- ak 3 plis
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
Ap rekriteFaz 2/3
- Washington University /ID# 280295, St Louis
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Mercy Infusion Center - Chippewa, St Louis
- Mercy Hospital South, St Louis
- Missouri Baptist Medical Center, St Louis
- ak 4 plis
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Ap rekriteFaz 1
- Washington University School of Medicine, St Louis
- Siteman Cancer Center-South County, St Louis
- Siteman Cancer Center at Christian Hospital, St Louis
- ak 1 plis
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- Washington University School of Medicine, St Louis
- Siteman Cancer Center-South County, St Louis
- Siteman Cancer Center at Christian Hospital, St Louis
- ak 2 plis
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Ap rekriteFaz 3
- Washington University in St Louis, St Louis
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- Washington University School of Medicine, St Louis
- Siteman Cancer Center-South County, St Louis
- Siteman Cancer Center at Christian Hospital, St Louis
- ak 2 plis
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- Washington University School of Medicine, St Louis
- Siteman Cancer Center-South County, St Louis
- Siteman Cancer Center at Christian Hospital, St Louis
- ak 3 plis
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Ap rekriteFaz 3
- Washington University School of Medicine, St Louis
- Mercy Hospital Saint Louis, St Louis
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Ap rekriteFaz 1/2
- Washington University in St. Louis School of Medicine, St Louis
A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
Ap rekriteEtid obsèvasyon
- Washington University in St. Louis, St Louis
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
Ap rekriteFaz 3
- US-St Louis MO-WASHU, St Louis
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
Ap rekriteFaz 1
- Washington University in St Louis, St Louis
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Ap rekriteFaz 1/2
- Cardinal Glennon Children's Medical Center, St Louis
- Washington University School of Medicine, St Louis
- Mercy Hospital Saint Louis, St Louis
Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML
Ap rekriteFaz 1/2
- Washington University School of Medicine, St Louis
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Ap rekriteFaz 3
- Washington University School of Medicine in St. Louis, St Louis
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Ap rekriteFaz 1
- Washington University School of Medicine, St Louis
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
Ap rekriteFaz 2
- Washington University, St Louis
Motixafortide for MRD Sensitization in AML
Ap rekriteFaz 2
- Washington University School of Medicine, St Louis
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Ap rekriteEtid obsèvasyon
- Cardinal Glennon Children's Medical Center, St Louis
- Washington University St. Louis, St Louis
- Washington University/St. Louis Children's Hospital, St Louis
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
Ap rekriteFaz 1
- Washington University in St. Louis, St Louis
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
Ap rekriteVolontè an sante akeyi
- Washington University School of Medicine, St Louis
Etid Leksemi mieloïd egi nan lòt vil
- Houston, TX85 etid
- New York City, NY51 etid
- Boston, MA44 etid
- Seattle, WA41 etid
- Baldwin Park, CA40 etid
- Columbus, OH35 etid
- Philadelphia, PA34 etid
- Durham, NC33 etid
- Atlanta, GA31 etid
- Tampa, FL29 etid
- Chicago, IL26 etid
- Portland, OR25 etid
Lòt etid nan St. Louis
- Kansè Poumon ki pa ti selil73 etid
- Kansè nan tete64 etid
- Kansè Metastatik54 etid
- Kansè kolorektal50 etid
- Kansè (tout kalite)46 etid
- Kansè pwostat46 etid
- Kansè poumon39 etid
- Kansè ovè38 etid
- Kansè pankreyas33 etid
- Kansè Endomèt29 etid
- Karsinòm selil skuamèz tèt ak kou28 etid
- Ensifizyans kadyak26 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.